Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma

SIMPLE SUMMARY: Sorafenib resistance is the major challenge for the unsatisfactory response to targeted therapies in advanced hepatocellular carcinoma (HCC). Combination therapy may overcome the obstacle and is an increasingly acceptable strategy. In this study, we demonstrate that niclosamide can i...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Syue-Wei, Ngo, Mai-Huong T., Kuo, Yung-Che, Teng, Ming-Hao, Guo, Chin-Lin, Lai, Hung-Cheng, Chang, Te-Sheng, Huang, Yen-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913083/
https://www.ncbi.nlm.nih.gov/pubmed/36765890
http://dx.doi.org/10.3390/cancers15030931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913083/
https://www.ncbi.nlm.nih.gov/pubmed/36765890
http://dx.doi.org/10.3390/cancers15030931

Ejemplares similares